Scholarlink

<p>Ovarian cancer remains one of the deadliest gynecological malignancies, with ~75% of cases diagnosed at an advanced stage due to the lack of effective screening. Standard treatment includes surgical tumor debulking and platinum-based chemotherapy. Despite high initial response rates, most patients experience recurrence and develop platinum resistance, thereby highlighting the need for novel therapies. The introduction of maintenance therapy with bevacizumab and poly(ADP-ribose) polymerase (PARP) inhibitors has revolutionized treatment, extending progression-free survival in both first-line and recurrent settings. Biomarkers like <i>BRCA</i> mutations and homologous recombination deficiency (HRD) guide treatment selection. While PARP inhibitors and antiangiogenic therapies have improved outcomes, immunotherapy has yet to show significant benefits in ovarian cancer. For early-stage disease, treatment is based on tumor stage, histology, and grading. Adjuvant chemotherapy benefits high-risk patients, though the optimal regimen remains uncertain. In advanced stages, platinum–taxane chemotherapy remains standard, with maintenance strategies now integrated. Emerging strategies include antibody–drug conjugates and treatment de-escalation approaches. These efforts aim to balance efficacy and toxicity, paving the way for personalized treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systemtherapie beim neudiagnostizierten Ovarialkarzinom

  • 期刊论文

  • 发表日期：

    2025年4月28日

查看全文
  • Nina Pauly,
  • Beyhan Ataseven

摘要

Ovarian cancer remains one of the deadliest gynecological malignancies, with ~75% of cases diagnosed at an advanced stage due to the lack of effective screening. Standard treatment includes surgical tumor debulking and platinum-based chemotherapy. Despite high initial response rates, most patients experience recurrence and develop platinum resistance, thereby highlighting the need for novel therapies. The introduction of maintenance therapy with bevacizumab and poly(ADP-ribose) polymerase (PARP) inhibitors has revolutionized treatment, extending progression-free survival in both first-line and recurrent settings. Biomarkers like BRCA mutations and homologous recombination deficiency (HRD) guide treatment selection. While PARP inhibitors and antiangiogenic therapies have improved outcomes, immunotherapy has yet to show significant benefits in ovarian cancer. For early-stage disease, treatment is based on tumor stage, histology, and grading. Adjuvant chemotherapy benefits high-risk patients, though the optimal regimen remains uncertain. In advanced stages, platinum–taxane chemotherapy remains standard, with maintenance strategies now integrated. Emerging strategies include antibody–drug conjugates and treatment de-escalation approaches. These efforts aim to balance efficacy and toxicity, paving the way for personalized treatment.